Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)
Developing and testing new interventions to enhance HIV prevention, treatment, and programs for individuals who use substances through formative research and pilot-testing.
Funder: National Institutes of Health
Due Dates: May 7, 2025 | September 7, 2025 | January 7, 2026 | May 7, 2026 | June 16, 2026 | July 16, 2026 | October 16, 2026 | November 16, 2026 | February 16, 2027 | March 16, 2027
Funding Amounts: Up to $450,000 direct costs over 3 years; no more than $225,000 in direct costs in any single year.
Summary: Supports formative research, development, and pilot-testing of novel or adapted interventions to improve HIV prevention, treatment, or service implementation for people who use substances, requiring a clinical trial.
Key Information: Clinical trial is required; strong end-user engagement and a theory of change or logic model must be included.
Description
This opportunity supports formative research, intervention development, and pilot-testing of interventions aimed at improving HIV prevention, treatment, and program implementation among people who use substances. The focus is on the feasibility, acceptability, tolerability, and safety of innovative or adapted interventions, which may include behavioral, social, structural, or combination biomedical and behavioral approaches. The goal is to prevent HIV acquisition and transmission or improve clinical outcomes for people living with HIV who use drugs. Projects must propose a clinical trial and should meaningfully engage end users (e.g., community members, practitioners, policymakers) in the research design and implementation.
